GlaxoSmithKline Biologicals' influenza vaccine GSK576389A — Competitive Intelligence Brief

GlaxoSmithKline Biologicals' influenza vaccine GSK576389A (GlaxoSmithKline Biologicals' influenza vaccine GSK576389A) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Vaccines.

phase 2 Influenza vaccine Influenza virus antigens Vaccines Biologic

Target snapshot

GlaxoSmithKline Biologicals' influenza vaccine GSK576389A (GlaxoSmithKline Biologicals' influenza vaccine GSK576389A) — GlaxoSmithKline. Induces an immune response against influenza viruses through the presentation of viral antigens to the immune system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GlaxoSmithKline Biologicals' influenza vaccine GSK576389A TARGET	GlaxoSmithKline Biologicals' influenza vaccine GSK576389A	GlaxoSmithKline	phase 2	Influenza vaccine	Influenza virus antigens
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
FluMist Quadrivalent (2017-2018)	FluMist Quadrivalent (2017-2018)	MedImmune LLC	marketed	Live attenuated influenza vaccine (LAIV)	Influenza virus
HD-TIV	HD-TIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine
Fluvirin(TIVf)	Fluvirin(TIVf)	Novartis	marketed	Inactivated influenza vaccine
Influsplit SSW® 2005/2006	Influsplit SSW® 2005/2006	GlaxoSmithKline	marketed	Inactivated influenza vaccine
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

1. GlaxoSmithKline · 8 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
3. Seqirus · 2 drugs in this class
4. MedImmune LLC · 1 drug in this class
5. AstraZeneca · 1 drug in this class
6. Novartis · 1 drug in this class
7. Protein Sciences Corporation · 1 drug in this class
8. ModernaTX, Inc. · 1 drug in this class
9. Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
10. Janssen Vaccines & Prevention B.V. · 1 drug in this class